It was reported that a progav 2.0 (#fx417t) was implanted during a procedure performed on (b)(6) 2020.According to the complainant, the valve showed difficulties in adjustment during a follow-up consultation.No further action is planned, the patient is stable and the valve remains implanted.
|
Due to the limited information and the missing product investigation is restricted to traceability of manufacturing and quality control data.An investigation was not possible, the product remains implanted.Regarding similar complaints where we could examine the products, we could determine that the most frequent cause for a deterioration in the function of the product are deposits caused by natural substances in the cerebrospinal fluid, e.G.Protein, blood or tissue particles.These are among the known and unavoidable risks and side effects of hydrocephalus therapy.Even small amounts of organic material can affect the integrity of the valve if aggregated in the valve.A final clarification of the cause what has led to adjustment difficulties is only possible by an examination.No further actions are required as a result of the complaint.
|